Evaxion receives grant funding to design new polio vaccine

Copenhagen, denmark, june 3, 2025 - evaxion a/s (nasdaq: evax) (“evaxion”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, receives funding support from the gates foundation to help the world eradicate polio (poliomyelitis) by exploring design options for a new and unique vaccine.

EVAX Ratings Summary

EVAX Quant Ranking